When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 1058-1063

  Kim, S J ^a   Oh, S Y ^b   Hong, J Y ^a   Chang, M H ^a   Lee, D H ^c   Huh, J ^c   Ko, Y H ^d   Ahn, Y C ^d   Kim, H J ^b   Suh, C ^c   Kim, K ^a   Kim, W S ^a  

^a Samsung Medical Center   (South Korea)

^b Dong A University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

CNS disease; Extranodal NK T cell lymphoma; Prognosis; Prophylaxis

Indexed keywords

ASPARAGINASE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER STAGING; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NK T CELL LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANASAL SINUS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RISK ASSESSMENT;

EID: 77953332514     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp412     Document Type: Article

References (27)

1. Aozasa K, Ohsawa M, Tajima K et al. Nation-wide study of lethal mid-line granuloma in Japan: Frequencies of wegener's granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditions. Int J Cancer 1989; 44: 63-66.
2. Laskin JJ, Savage KJ, Voss N et al. Primary paranasal sinus lymphoma: Natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma 2005; 46: 1721-1727.
3. Oprea C, Cainap C, Azoulay R et al. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: A report of 14 cases. Br J Haematol 2005; 131: 468-471.
4. Cheung MM, Chan JK, Lau WH et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: Clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70-77.
5. Cuadra-Garcia I, Proulx GM, Wu CL et al. Sinonasal lymphoma: A clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol 1999; 23: 1356-1369.
6. Kim GE, Koom WS, Yang WI et al. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck 2004; 26: 584-593.
7. Kim BS, Kim DW, Im SA et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol 2009; 20: 121-128.
8. Yamaguchi M, Suzuki R, Kwong YL et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99: 1016-1020.
9. Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal type: A prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-618.
10. Lee J, Park YH, Kim WS et al. Extranodal nasal type NK/T-cell lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005; 41: 1402-1408.
11. van Besien K, Ha CS, Murphy S et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91: 1178-1184.
12. MacKintosh FR, Colby TV, Podolsky WJ et al. Central nervous system involvement in non-Hodgkin' lymphoma: An analysis of 105 cases. Cancer 1982; 49: 586-595.
13. McMillan A. Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol 2005; 131: 13-21.
14. Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin' lymphoma: A review of the literature. Semin Neurol 2004; 24: 395-404.
15. Spectre G, Gural A, Amir G et al. Central nervous system involvement in indolent lymphomas. Ann Oncol 2005; 16: 450-454.
16. Zucca E, Conconi A, Mughal TI et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20-27.
17. Jeanneret-Sozzi W, Taghian A, Epelbaum R et al. Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer 2008; 8: 86.
18. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by nonHodgkin's lymphoma: The risk factors. Hematol Oncol 1990; 8: 141-145.
19. Shikama N, Oguchi M, Sasaki S et al. Evaluation of central nervous system involvement in nasal lymphomas. Nippon Igaku Hoshasen Gakkai Zasshi 2001; 61: 342-346.
20. Hollender A, Kvaloy S, Lote K et al. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 2000; 36: 1762-1768.
21. Bashir RM, Bierman PJ, Vose JM et al. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 1991; 14: 478-482.
22. Zinzani PL, Magagnoli M, Frezza G et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: The Bologna experience. Leuk Lymphoma 1999; 32: 571-576.
23. Feugier P, Virion JM, Tilly H et al. ncidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab. Ann Oncol 2004; 15: 129-133.
24. Boehme V, Zeynalova S, Kloess M et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18: 149-157.
25. Kim TM, Park YH, Lee SY et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106: 3785-3790.
26. Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000; 11: 685-690.
27. van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: Risk, prophylaxis and treatment. Leuk Lymphoma 2008; 49 (SUPPL 1): 52-58.